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Summary Glioma tumour growth is associated with the expression of insulin-like growth factors and 11 (IGFs) and of both type and type 11
IGF receptors. It has also been shown that IGFs can stimulate proliferation of cultured glioma cells. We previously reported that histamine too
can stimulate the growth of glioma cells in vitro. In this report, we study whetherthe histamine-induced growth of G47glioma cells is mediated
by the IGFs. We found that histamine stimulates the expression of both IGF-I and IGF-11 mRNAs, as determined by a semiquantitative in situ
hybridization analysis. Furthermore, incubation of G47 cells with histamine also induced cellular immunostaining for IGF-11. It could be shown
that IGF-I-stimulated proliferation is inhibited by IGFBP-3, which decreases the availability of IGFs for binding to the IGF receptors, and by
P-galactosidase, which may decrease IGF binding to the type 11 IGF receptor, but is not inhibited by the anti-type IGF receptor monoclonal
antibody alR3. However, neither IGFBP-3 nor P-galactosidase nor alR3 inhibited the histamine-induced proliferation. These results show that
the growth-stimulatory effect of histamine is accompanied bythe induction of IGFs. This histamine-induced growth stimulation is not mediated
by activation of cell surface IGF receptors, although intracrine activation of type 11 IGF receptors may be involved.
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Glioma tumorigenesis has been associated with overexpression of
several growth factors and their receptors, including the insulin-
like growth factor (IGF) system (Antoniades et al, 1992). The
importance of the IGF system in tumour growth is illustrated by
the vast number of cancer types in which aberrant expression of
IGF-I, IGF-II, their receptors or binding proteins (IGFBPs) has
been described (reviewed in Macaulay, 1992). IGFs may be
important for glioma cell growth, suggested by the presence in
these tumours of both IGF-I and IGF-II mRNAs and peptides
(Glick et al, 1991; Antoniades et al, 1992), as well as the presence
ofthe type I and II IGF receptors (Glick et al, 1989; Antoniades et
al, 1992). Furthermore, glioma membrane preparations have
increased specific IGF-I binding capacity compared with normal
brain tissue (Merrill and Edwards, 1990). IGFBPs of variable
affinity and/or variable molecular weight were found in membrane
preparations of surgical glioma specimens (Merrill and Edwards,
1990) or in conditioned medium of primary or established malig-
nant glioma cell lines (McCusker et al, 1990; Unterman et al,
1991). Also, IGF-I could stimulate DNA synthesis in primary
malignant glioma cultures (Merrill and Edwards, 1990; Pollack et
al, 1991), and, in the rat C6 glioma cell line, reduction of IGF-I
mRNA levels was associated with decreased DNA synthesis
(Lowe et al, 1992); transfection ofthese cells with antisense IGF-I
RNA prevented in vivo tumour growth (Trojan et al, 1993). Some
glioma cell lines also produce IGF-II (Glick et al, 1992), and the
growth rate ofthe LI human glioblastoma cell line correlated with
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IGF-II expression; growth arrest in this cell line was accompanied
by decreased IGF-II expression (Melino et al, 1992).
IGF gene expression is regulated by a number of factors
(reviewed in Schofield, 1991; Simmen, 1991). Some examples of
endocrine and paracrine regulators of IGF expression are growth
hormone, thyroid hormone, steroid hormones and several growth
factors. Previously, we have reported the proliferation stimulating
capacity of histamine in established and low passage primary
glioma cell lines (Van der Ven et al, 1993a). Histamine is a
biogenic amine derived from L-histidine. It is formed in mastcells,
basophils, platelets and neurons, and also in proliferating tissues
such as repairing wounds, embryos and tumours (Kahlson and
Rosengren, 1968). Apart from its well-recognized regulation of
vegetative functions like inflammation, smooth muscle tension and
gastric acid secretion, histamine has been shown to function as a
growth factor in vitro (e.g. Panettieri et al, 1990; Tilly et al, 1990;
Hellstrand and Hermodsson, 1991; U,ar, 1991). It can exert this
action in an autocrine way (Schneider et al, 1990; Cricco et al,
1994; Suonio et al, 1994). The stimulation ofproliferation may be
a direct effect oftriggering classical signal transduction pathways
via the H1- and the H2-receptors (reviewed in Bloemers, 1993),
leading to DNA synthesis. Alternatively, stimulation of prolifera-
tion may also be due to the induction of the expression of other
factors. In this respect, histamine has been shown to modulate the
expression of a number of cytokines, i.e. interleukin 1 (IL-1)
(Vannier and Dinarello, 1993), interleukin 6 (IL-6) (Vannier and
Dinarello, 1994), tumournecrosis factoralpha (TNF-a) (Vannieret
al, 1991) and y-interferon (Richtsmeier et al, 1987). In this report,
we investigate whether histamine can modulate the production of
IGFs in agliomacell line and whethertheproliferation-stimulatory
effect ofhistamine in this cell line is mediated by IGFs.
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MATERIALS AND METHODS
Cell line and culture conditions
The PU-G47 human cell line (further called G47) was established
in our laboratory from a highly malignant glioma and characterized
previously (Van der Ven et al, 1993a). Usually, cells were cultured
in medium consisting of Dulbecco's modified Eagle medium
(DMEM, Gibco, Chagrin Falls, OH, USA) with 10% fetal calf
serum (FCS, EU approved, Gibco) and further supplemented as
described (Van der Ven et al, 1993a). For the experiments, cells
suspended in regular culture medium were seeded in a density of
1.2 x 104 cells per cm2 in appropriate culture devices. These were
eight-chamber slides (LabTek, Nunc, Gibco) for the in situ detec-
tion of IGF mRNA and peptide, 25-cm2 culture flasks (Costar,
Cambridge, MA, USA) for collection of conditioned medium for
IGF quantification and 96-well plates (Costar) for the proliferation
assays. The next day, cells were washed with phosphate-buffered
saline (PBS: 150 mm sodium chloride, 8.6 mm disodium hydrogen
phosphate dihydrate, 1 mm potassium hydrogen phosphate, pH 7.3;
all from Riedel de Haen, Seelze, Germany), and assay medium was
added. This consisted ofDMEM/Ham's F12 medium (1:1, Gibco),
supplemented as regular culture medium but without insulin and
with only 0.5% serum. In initial experiments, it appeared that
histamine-induced effects were more distinctive when tested with
other types of serum (goat/chicken) than FCS. The presented
experiments were performed using FCS, with exception of the
growth assays. These were done using goat serum, because this
selection represents the most comprehensive set of tests. Chicken
and goat serum were prepared by immediate centrifugation of
freshly obtained blood. After another day, histamine (free base,
Sigma Chemicals, St Louis, MO, USA) was added to a final
concentration of 0.2 mm. Controls received no histamine. For the
proliferation assays, the additions also included 100 ng ml-' human
IGF-I (GroPep, Adelaide, Australia), 2.9 ,tg ml-' recombinant
human IGFBP-3 (E. coli derived, non-glycosylated, Celtrix
Pharmaceuticals, Santa Clara, CA, USA, kindly provided by Dr A
Sommer and Dr CA Maack), 1 pig ml-' ofthe type I IGF receptor-
blocking monoclonal antibody (aIR3, lyophilized, Oncogene
Science, Manhassat, NY, USA) or 1 pig ml-' ,-galactosidase
(Boehringer, Mannheim, BRD), which is a competitive inhibitor of
type II IGF receptor binding (Kiess et al, 1990).
Detection of IGF-I and IGF-11 mRNA
Incubation of the cultures in the LabTeks (see section on cell line
and culture conditions) was ended at times varying between 1-
24 h after addition of histamine by detaching the wells from the
slides, rinsing the slides quickly in PBS and fixing the cells with
4% phosphate-buffered formaldehyde (Klinipath, Duiven, The
Netherlands) for 10 min. Slides were then dehydrated by putting
them quickly through a series of70%, 96% and 100% ethanol, and
then air-dried. Specific mRNAs were detected by in situ hybridiza-
tion (Wilkinson and Green, 1992), with probes for human IGF-I
and human IGF-II. The probes were prepared by linearizing cDNA
of IGF-I (pIGF-I, exons 1, 3 and 4; 777 base pairs; Jansen et al,
1983) and of IGF-II (pIGF-IIvar, exons 3, 7, 8 and 9; 713 base
pairs; Jansen et al, 1990). The cDNAs were cloned in the vector
pBluescript-KS (Stratagene, La Jolla, CA, USA), and transcribed
with T3 RNA polymerase (Boehringer) in the presence of [35S]
UTP (Amersham, Amersham, UK), according to the manufac-
turers' protocol, to obtain antisense RNA with a specific activity
of 109 c.p.m tg-' RNA. Specificity of these probes in the in situ
hybridization was tested on tissues with confirmed presence or
absence of the mRNAs by Northern blotting. In the in situ
hybridization, cells were rehydrated, permeabilized in Triton
X-l00 (Boehringer), treated with 10 [tg ml-' proteinase K
(Boehringer), acetylated and dehydrated. The slides were incu-
bated overnight at 55°C with 30 [tl of hybridization buffer
containing labelled probe in a concentration of 200 000 per 30
c.p.m. dl-' and, after several washing steps, cells were dehydrated
in a series of ethanol containing 0.3 M ammonium acetate, air-
dried and exposed to a Storage Phosphor Screen (Molecular
Dynamics) for 8-48 h, depending on the signal intensity. This
screen was scanned with a Phosphor Imager (Molecular
Dynamics), and the signal ofthe wells was quantified.
Detection of IGF-I and IGF-II peptides
Cells were cultured in the LabTeks (see section on cell lines and
culture conditions) for 1-3 days. The cultures were ended by
detaching the wells from the slides, rinsing the slides with PBS and
fixing the cells in acetone for 10 min. These slides were incubated
with specific rabbit polyclonal antisera for IGF-I and IGF-II [batch
no. 878/4 and no. C41 respectively, kind gifts from Dr BH Breier,
Auckland, NZ, and characterized for use in immunohistochemistry
by Klempt et al (1992); both antisera were used in a dilution of
1:200]. Control slides were incubated without the primary anti-
body. The standard immunocytochemical procedure includes a
preincubation with 10% normal goat serum (NGS, Vector
Laboratories, Burlingame, CA, USA) in PBS containing 0.1%
Tween-20 (Sigma; PBS/t), incubation with the primary antibody in
1% NGS in PBS/t (1 h) and incubation (30 min) with abiotinylated
second antibody (goat anti-rabbit, Vector, 1:200) dissolved in PBS/t
with 1% NGS. These steps were alternated with adequate washes
with PBS/t. The bound immune complex was visualized with
horseradish peroxidase-avidin-biotin complex (Vector), according
to the instructions of Vector. As a chromogenic substrate for the
horseradish peroxidase, we used 3,3'diaminobenzidine (DAB,
Merck) in a 10-min incu'bation followed by a rinse in tap water.
Nuclei were counterstained with haematoxylin. Immunostained
cells were dehydrated in ethanol/xylene and embedded in DePeX.
For determination of IGFs in the culture supernatant, medium
from cultures in 25-cm2 culture flasks, prepared as described
above, was harvested at day 3, freeze-dried and redissolved in
distilled water in 1:20 ofthe original volume. Samples of250 tl of
this concentrated medium were extracted under acid conditions
usingC1,8 SepPak cartridges (SepPak, Waters, Milford, MA, USA).
The C1 extraction method adequately eliminates IGF binding
proteins from conditioned media to such an extent that interfer-
ence with the radioimmunoassay is not to be expected (Van der
Ven et al, 1994). IGFs were measured in a routine radio-
immunoassay as described previously (Jansen et al, 1990; Van
Buul-Offers et al, 1994). The recovery of recombinant human
IGF-I when added to human plasma was 84 + 14%. For IGF-II,
these values were in a similar range. These results support the
adequacy ofthe C18 extraction method.
Proliferation assay
Forproliferation stimulation experiments, cultures were prepared in
96-well plates as described above. The cell density was measured at
3-day intervals within 7 days after seeding (at days 1, 4 and 7) with
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Figure 1 Induction of IGF-I mRNA (A) and IGF-Il mRNA (B) after a single dose of 0.2 mm histamine at t = 0 as a function of time. Results are presented as the
increase in signal emerging from G47 cells cultured in eight-chamber slides with histamine relative to unstimulated cultures after in situ hybridization with IGF-I-
or IGF-II-specific probes. The culture medium was supplemented with 0.5% FCS. Large dots represent the mean of duplicate observations (small dots). The
histamine-induced increase in both IGF-I and IGF-Il mRNA expression is significant in an ANOVA over the entire observation period (P <0.05)
Figure 2 Increase in immunocytochemical staining intensity for IGF-Il in G47 after 3 days of incubation with (+) or without (-) histamine. IGF-Il peptide is
detected in the cytoplasm and in the nucleus (arrows). Scale bar = 30 iLm. Immunoperoxidase DAB staining with haematoxylin counterstaining
a colorimetric assay (Van der Ven et al, 1993b). Briefly, the wells
were subsequently incubated with glutaraldehyde (25%) and
methylene blue (0.05%) and, after each incubation, the wells were
rinsed with tap water. Finally, the bound dye was extracted from the
cells with 0.33 M hydrochloric acid. The extinction resulting from
the extracted dye was measured at 620 nm in a Titertek multiscan
spectrophotometer. Extinction values of 1500-65 000 cells per well
as counted with a haemocytometer ranged from 0.020 to 1.100. As
a measure for the growth rate, the number ofpopulation doublings
(PD) in n-I days was calculated from extinction values measured
on these days (En and El) using the formula PD = 2log (En/EI).
Results ofthe growth experiments are presented as the difference of
the mean numberofPD in 5 or6control and test wells. Significance
ofdifferences between the variouscultureconditions was calculated
in a two-tailed Student's t-test.
RESULTS
Induction of IGF mRNAs by histamine
Both IGF-I and IGF-II mRNAs were detected with quantified in
situ hybridization in G47 cells cultured in 0.5% serum. Histamine
treatment induces a significant increase of both IGF-I and IGF-II
mRNA levels during the 4-h observation period (Figure 1). After
stimulation with histamine, the maximum expression level ofboth
IGF mRNAs is approximately twice that of the basal expression
level. IGF-II mRNA expression is stimulated more rapidly than
IGF-I mRNA expression. The results presented in Figure 1 are
obtained in FCS. Similar results with respect to level and kinetics
of the increase of expression of both IGF mRNAs are observed
when G47 cells are cultured in medium containing other types of
serum (not shown).
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Figure 3 (A) Effect of 0.2 mm histamine (h) or 100 ng ml-' IGF-I (I) or h and combined on the growth of G47, given as the increase in population doublings
relative to the unstimulated control growth curve, measured 7-8 days after initiation of the experiment. Population doublings are calculated as indicated in
Materials and methods. (B, C and D) Effect of (B) 2.9 gg ml-' IGFBP-3 (b), (D) 1 gl ml-' aIR3 (a) or (D) 1 ,tg ml-'1-galactosidase (p) on the growth of the
histamine and IGF-I-stimulated cultures. For comparison, the effect of the factors alone is also shown. Experiments were done quintuplicate or sextuplicate;
error bars indicate s.e.m. The significance of the difference of each single addition compared with the unstimulated control growth curve (0 level) is indicated by
an asterisk. The other symbols indicate the significance of the combination of factors in each triplet compared with each factor alone: # with the left factor and
+ with the right factor. One symbol = P < 0.05 and two symbols = P < 0.005
Induction of IGF peptides by histamine
It was possible for a histamine-induced increase of IGF mRNA
expression to be followed by an increase in IGF peptide levels.
Indeed, immunostaining of G47 cells showed a histamine-induced
increase in IGF-II in the cytoplasm and in the nucleus (Figure 2). As
forIGF-I, no increase in immunostaining in G47 cells was observed
after stimulation with histamine. A radioimmunoassay of day 3
culture media showed very low IGF levels (< 1.3 ng ml-' IGF-I and
< 2.4 ng ml-' IGF-II), and there was no detectable increase in either
IGF-I or IGF-II levels after stimulation with histamine.
Modulation of growth by histamine and IGF-I through
stimulation of the IGF receptors
Growth ofG47 cells was stimulated significantly by histamine and
also by IGF-I (Figure 3A). The concentration of histamine used
proved to be maximally effective in this cell line (not shown), and
the concentration of IGF-I used proved to be twice the concentra-
tion that was maximally effective in other malignant glioma cell
lines (Pollack et al, 1991). IGF-I had an additive effect on
histamine-stimulated growth, whereas histamine did not affect
IGF-I-stimulated growth. The histamine-induced expression of
IGFs suggests the possibility that histamine-stimulated prolifera-
tion was mediated by IGFs. We therefore tested whether the hista-
mine-stimulated proliferation could be inhibited by the addition of
IGFBP-3, which limits the binding of the IGFs to the IGF recep-
tors. Figure 3B shows that binding ofIGFs in the culture medium
with IGFBP-3 inhibits the action of IGF-I significantly, whereas
histamine-stimulated proliferation is unaffected. The type I IGF
receptor-binding antibody aIR3 did not block the histamine-
induced proliferation or the IGF-I-induced proliferation (Figure
3C). In contrast, aIR3 induced a significant increase in population
doublings in all tested conditions, i.e. when added alone or
combined with histamine or IGF-I; in the latter case compared
with the effect of the factor alone. Addition of P-galactosidase
(Figure 3D) did not affect the stimulation ofhistamine, whereas it
completely blocked the IGF-I-induced effect, suggesting that the
IGF-I-induced effect is mediated through activation of the type II
IGF receptor. Experiments that were repeated using different types
of serum had a similar outcome.
DISCUSSION
Induction of IGF-I and IGF-II mRNA and peptides by
histamine
The results indicate that histamine can induce the expression of
mRNAs of both IGFs. The concept of histamine as a modifier of
relevant gene activity is supported by findings in other cell types.
Histamine modulates the expression ofvarious cytokines in blood
mononuclear cells (Vannier et al, 1991; Vannier and Dinarello,
1993, 1994), of y-interferon in lymphocytes (Richtsmeier et al,
1987), ofthe IL-6 receptor in a variety ofcell types (Meretey et al,
1991), of c-fos in smooth muscle cells (Panettieri et al, 1990),
of immunoglobulins in B cells (Fujimoto and Kimata, 1994) and
of collagen I in fibroblasts (Kikuchi et al, 1995). The importance
of the induced IGF expression in G47 glioma cells is indicated by
the concomitant induction ofIGF-II peptide (Figure 2). The poten-
tial ofhistamine to induce IGF expression adds this factor to many
endocrine and auto/paracrine factors, such as peptide and steroid
hormones and several growth factors, which can act as regulators
of IGF expression in various systems (Schofield, 1991; Simmen,
1991). Also, in glioma cells, IGF expression is aregulated process,
as is illustrated in the C6 glioma cell line. In these cells, dexa-
methasone and retinoic acid reduce IGF-I mRNA levels, whereas
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epidermal growth factor (EGF) increases IGF-I expression (Lowe
et al, 1992). This is also the case in normal rat astrocytes, and in
these cells IGF-I even mediates EGF-stimulated proliferation
(Chemausek, 1993). The specificity of the detected induction of
IGF expression is supported by the finding that histamine-induced
specific stimulation of IGF-I expression in one of three other
glioma cell lines (U138, not in PU-G223 and U373) and ofIGF-II
expression in two out of three of these cell lines (U138 and PU-
G223, not in U373) in similar culture conditions (data not shown).
Basal immunocytochemical staining was shown for both IGFs, but
the observed induction ofIGF mRNAs by histamine was followed
by a distinct increase only in intracellular IGF-II. This suggests
that both IGFs are produced and thatIGF-II, in contrast to IGF-I, is
also retained intracellularly or reintemalized after secretion. Both
IGFs were also found in conditioned medium, and the low levels
measured were within the range reported by others in the condi-
tioned media of glioma cultures over the same culture period
(Glick et al, 1992). The rapid induction of IGFs may be sufficient
to promote growth without resulting in measurable changes in IGF
levels in the culture supernatant 3 days later, specific or non-
specific proteolytic activity may exceed the low-level production
ofthe peptides. Furthermore, the presence oflow amounts ofIGF-
containing serum could mask low levels ofIGFproduction. On the
other hand, the absence of increased IGF levels in the culture
media after stimulation with histamine corresponds with the
absence ofeffect ofIGF blocking agents on the histamine-induced
cell population growth; both observations suggest that the
histamine-induced population growth is not dependent on extra-
cellular accumulation ofIGF levels.
IGF-I-stimulated proliferation
Growth of G47 cells was stimulated by IGF-I, corresponding
with previously reported results in other glioma cell lines (Merrill
and Edwards, 1990; Pollack et al, 1991; Chernausek, 1993).
Expression ofboth IGF receptors has also been identified in gliomas
(Antoniades et al, 1992). The specific importance of type II IGF
receptors forcells ofthe glial lineage is suggested by thepresence of
high levels of this receptor, but not of type I IGF receptors, in a
human glioblastoma cell line (Laurenzi et al, 1995) and by the pref-
erential endocytosis ofIGF-IH by rat neonatal astrocytes (Auletta et
al, 1992). Inmostothersystems, thetype I IGFreceptors mediate the
mitogenic effectofboth IGF-I andIGF-II (Nissley andLopaczynski,
1991), and aIR3 generally inhibits IGF-I-stimulated growth (Nissley
and Lopaczynski, 1991; Van der Ven et al, 1993b). However, the
type H IGF receptor has been implicated as a mediator of IGF-
induced growth-stimulatory effects in other models (reviewed in
Nissley and Lopaczynski, 1991; additional observations in Mathieu
et al, 1990, De Leon et al, 1992 and Fournier et al, 1993). We found
that 3-galactosidase, but not aIR3, completely inhibits IGF-I-
stimulated growth in G47 cells. As ,3-galactosidase is an inhibitor
of type II IGF receptor binding (Kiess et al, 1990), these results
suggest that this IGF-I-stimulated growth is mediated only through
the type II IGF receptor. The importance of the type H receptor in
these cells is further suggested by the intracellular increase in specif-
ically IGF-Il levels, possibly because of selective binding ofIGF-II
by the type H IGF receptor, which preferentially binds IGF-H
(Nissley and Lopaczynski, 1991). In a preliminary binding experi-
mentofradiolabelled IGF-I and-Il tointactG47 cells, eitheralone or
blocked by ,-galactosidase, we obtained no conclusive results (data
not shown); more detailed study should clarify this point.
Surprisingly, in G47 cells, aIR3 could stimulate population
growth when added alone. A similarresult was obtained in another
glioma cell line, U138 (data not shown). Agonistic activity of
aIR3 was also suggested in other systems (Roth et al, 1988; Steele
Perkins et al, 1988; Mathieu et al, 1990; De Leon et al, 1992; Kato
et al, 1993). However, the observation that aIR3 enhanced IGF-I-
stimulated proliferation, in contrast to an expected blocking effect,
suggests that aIR3 modulates the binding of IGF-I to other G47
cell-surface binding sites than the type I IGF receptors.
IGF as mediator for the histamine-induced proliferation
Neither ofthe two factors that blocked the IGF-I-induced stimula-
tion of growth (i.e. IGFBP-3 and j-galactosidase) affected the
histamine-induced stimulation, indicating that histamine-
stimulated proliferation of G47 cells is not mediated by secreted
IGFs. Separate mechanisms for histamine- and IGF-I-stimulated
growth are also suggested by the presence of an additive effect of
IGF-I stimulation on histamine stimulation (Figure 3A), although
this is not confirmed by the absence of an additive effect ofhista-
mine on IGF-I-stimulated growth. This paradoxical finding indi-
cates either that these factors use a common post-receptor pathway
that is maximally activated by IGF-I alone but not by histamine
alone or, in the case of separate activating pathways, that other
culture conditions limit the rate of proliferation. However, hista-
mine-induced IGF-II may act in an intracrine fashion (Logan,
1990), supported by the increased intracellular immunostaining of
IGF-II after histamine stimulation.
CONCLUSION
Histamine could induce the expression of IGF mRNAs in G47
gliomacells andcould also induce an increase ofcell-bound IGF-II.
Factors that blocked the proliferation-inducing effect of supple-
mented IGF-I did not affect the histamine-stimulated proliferation,
indicating that this effect is not mediated by secreted IGFs.
Nevertheless, itremains conceivable that histamine-induced IGF-LI
acts in an intracrine fashion, as suggested by the increased intracel-
lular staining of IGF-II. IGF-I-induced stimulation ofproliferation
ofG47 cells is not mediated by the type I IGF receptor, whereas the
inhibiting effect of P-galactosidase on IGF-I-stimulated prolifera-
tion suggests a function ofthe type II IGF receptor.
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